Turner Investments’s Standard BioTools LAB Stock Holding History

Turner Investments’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-52,780	Closed	-$2.22M	–	330
2015 Q1	$2.22M	Buy	+52,780	New	+$2.09M	0.4%	81

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Turner Investments's LAB Position: Q2 2015 in Review

Turner Investments sold out of Standard BioTools (LAB) in Q2 2015, closing a stake of 52,780 shares — an estimated $2.22M sold.

Turner Investments first reported a position in LAB in Q1 2015 and held it in 1 quarter. The position peaked at $2.22M in Q1 2015. 107 funds tracked by Wall St. Rank hold LAB as of Q2 2015.

Turner Investments reported no remaining Standard BioTools position as of Q2 2015 after selling out during the quarter.
Turner Investments sold 52,780 Standard BioTools shares in Q2 2015, an estimated $2.22M.
Turner Investments first reported a position in Standard BioTools in Q1 2015 and held it in 1 quarter.
Turner Investments's Standard BioTools position peaked at $2.22M in Q1 2015.
107 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2015.

Based on Turner Investments's 13F filing for Q2 2015, filed 12 Aug 2015.